Morning Overview on MSN
The FDA approved a Pfizer RSV vaccine for at-risk adults as young as 18
Adults between 18 and 59 who face elevated risk of severe respiratory syncytial virus infection now have a licensed vaccine option. The FDA issued a supplement approval letter for Pfizer’s Abrysvo on ...
Pfizer Inc. (NYSE:PFE) is one of the 8 Worst Blue Chip Stocks to Buy Now. On July 10, 2026, Pfizer Inc. (NYSE:PFE) and ...
PFE, received FDA approval for a platinum-free Padcev-Keytruda regimen in muscle-invasive bladder cancer. The regimen is ...
Approval expands HYMPAVZI use to now include people with hemophilia A or B ages 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors HYMPAVZI is ...
Celcuity has won FDA approval for gedatolisib – its first product – as a treatment for patients with a particular form of ...
The U.S. FDA on Tuesday granted traditional approval for a first-line combination regimen involving Braftovi, an oral cancer drug developed by Pfizer (PFE) in partnership with companies such as ...
Pfizer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Hympavzi hemophilia drug for two patient populations with significant medical need ...
When Lyme disease makes the news, it's typically not for positive reasons — but Pfizer is gearing up to seek regulatory approval for a new vaccine candidate, CNBC reported. In April 2020, Pfizer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results